Investment Rating - The report maintains a "Strong Buy" rating for the company [2][5]. Core Insights - The company achieved a revenue of 17.231 billion yuan in 2025, representing a year-on-year growth of 10.92%, while the net profit attributable to shareholders was 1.155 billion yuan, down 4.13% year-on-year [3]. - The functional products segment saw a revenue increase of 11.12% to 12.914 billion yuan, driven by strong sales of liquid methionine, which reached a historical record in global market penetration [3]. - The special products segment also performed well, with a revenue increase of 10.31% to 4.316 billion yuan, particularly in North America and Europe, where sales of ruminant products grew over 20% [3]. - The company has implemented an "Operational Efficiency Improvement Plan" since 2019, which has helped reduce regular operating costs by 230 million yuan, showcasing strong cost competitiveness [3]. - The company is expanding its methionine production capacity, with significant projects underway, including a 150,000-ton solid methionine plant in Quanzhou, expected to start trial operations by the end of 2026 [4]. Financial Performance Summary - The company forecasts net profits of 1.454 billion yuan, 1.682 billion yuan, and 1.864 billion yuan for 2026, 2027, and 2028, respectively, with corresponding EPS of 0.47 yuan, 0.55 yuan, and 0.61 yuan [5]. - The projected revenue growth rates for the next few years are 8.50% for 2026, 9.75% for 2027, and 10.50% for 2028 [6]. - The comprehensive gross margin decreased by 1.90 percentage points to 28.31% [3].